Newsletter | August 9, 2022

08.09.22 -- Reshaping Supply Chains In Response To COVID-19

 
Effects Of The Ongoing Pandemic On Bupivacaine HCI Supply
 

Throughout the pandemic, painkiller and sedative demands have spiked. Drug manufacturers and CDMOs have become critical in efforts to stabilize the supply of Bupivacaine HCl and other essential drugs.

Ensuring Resilience: How Life Sciences Is Reshaping Supply Chains In Response To COVID-19
 

Understand how the supply chain experience, severely affected by COVID-19, involving global workforce disruption, surging demand, and drug shortage notices, is shaping attitudes toward resilience.

Speed-To-Market: API Large Scale Commercial Manufacturing
 

A pharmaceutical company was looking to partner with a CMO with commercial manufacturing capabilities, large-scale assets, multinational sites, and exemplary quality systems/US FDA track record.

Investing In Capacity: API Commercial Manufacturing
 

A pharmaceutical company sought a CMO partner with commercial manufacturing capabilities and expertise and exemplary quality systems to find a cost-effective process to produce the API for a new drug.